Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

GPhC received 25 whistleblowing disclosures in a year

The General Pharmaceutical Council (GPhC) has revealed it has received 25 whistleblowing disclosures between April 2021 and March 2022.

The pharmacy regulator said, in its annual report, that it has concluded enquiries on 22 disclosures so far with a further three still under review.


“We also concluded two qualifying disclosures that were raised during the previous reporting period,” it said, adding: “The action GPhC took included a full investigation through established fitness to practise processes and follow-up action through its inspection network.

“The former can result in any available outcome throughout the fitness to practise process. The latter can include guidance, a follow-up visit or an unexpected inspection.”

12 concerns were investigated and concluded with no further action. Three were signposted to another organisation. The remaining seven cases were concluded by sharing information with inspection colleagues for follow up action.

Of the two concerns from the previous reporting period, one was concluded with no further action and the other remains under investigation.

The GPhC said: “None of the disclosures had an impact on our ability to perform our regulatory functions and meet our objectives during the reporting period. We use all concerns raised with us to inform our standards and guidance development.”

“Protected disclosures also inform our operational processes and approach to understanding what the most appropriate regulatory lever is to achieve the best outcome.

“The concerns raised with inspectors and the associated guidance in response to the concerns, including those that arise through inspections, are widely shared to ensure learning across the organisation. These issues inform our work on understanding the experiences of pharmacy professionals in the working environment and also inform our work on ensuring safe and effective pharmacy teams.”

The GPhC, in conjunction with seven other healthcare professional regulators, published its annual report on whistleblowing disclosures. All prescribed bodies have a legal responsibility to publish an annual report on the whistleblowing disclosures made to them by workers.

More For You

Screening newborn babies for rare diseases will involve sequencing their complete DNA

Screening newborn babies for rare diseases will involve sequencing their complete DNA

iStock

DNA test for all babies to study disease risk

Key Summary

  • The DNA of newborn babies will be sequenced using blood samples from their umbilical cord
  • The government will invest £650m in DNA research for all patients by 2030
  • Genomics and AI would be used for faster diagnoses

Children born in England will have their DNA mapped to screen for hundreds of diseases under the NHS plan for the next 10 years.

Keep ReadingShow less
Uneven HPV vaccine uptake increases cervical cancer risk: UKHSA

UKHSA data shows that the uptake of the HPV vaccines for boys and girls was the lowest in London and highest in the south-east.

iStock

Uneven HPV vaccine uptake increases cervical cancer risk: UKHSA

The UK Health Security Agency (UKHSA) has warned that variations in geographical coverage of Human Papillomavirus (HPV) vaccine in adolescents across England is leaving many with less protection against cervical and some other cancers.

Data provided by Cancer Research UK indicates that cervical cancer rates in England are 65 per cent higher in the most deprived quintile compared with the least.

Keep ReadingShow less
Lung Cancer

Serplulimab helps immune cells recognise and destroy cancer cells more effectively.

iStock

Serplulimab gets MHRA approval for treating small cell lung cancer

The monoclonal antibody Serplulimab has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat adults with extensive-stage small cell lung cancer.

This cancer develops in the airways of the lungs and spreads fast within the lungs and other parts of the body.

Keep ReadingShow less
FCI scanner developed in Aberdeen aims to detect glioblastoma more safely than MRI scans

The Field Cycling Imaging scanner developed at the University of Aberdeen will provide more precise images than MRI scans

iStock

New scanner could improve brain tumour treatment

A new type of scanner shows promise in generating never-before-seen brain tumour images and is expected to help in treatment of glioblastoma patients.

The Field Cycling Imaging (FCI) scanner developed at the University of Aberdeen will provide more precise images than MRI scans.

Keep ReadingShow less
St James's University Hospital , NHS

Care Quality Commission downgraded the maternity and neonatal services at St James's University Hospital and Leeds General Infirmary.

Getty images

Two Leeds maternity units downgraded after inspection

The NHS regulator has downgraded two hospitals in Leeds to "inadequate" from "good" following an inspection.

The Care Quality Commission (CQC) said the maternity and neonatal services at Leeds General Infirmary (LGI) and St James' University Hospital of the Leeds Teaching Hospitals (LTH) NHS Trust posed "a significant risk" to women and babies.

Keep ReadingShow less